Navigation Links
MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
Date:1/31/2008

VANCOUVER and SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, will add a 600mg celgosivir combination therapy arm to its currently enrolling Phase II viral kinetics study in hepatitis C virus ("HCV") treatment-naive patients. The protocol amendment to this study has received Health Canada and Institutional Review Board (IRB) approvals. The purpose of this new treatment arm is to assess 600mg celgosivir (an oral alpha glucosidase I inhibitor) for tolerability, pharmacokinetics and viral kinetics when combined with the standard of care drugs, pegylated interferon plus ribavirin, as compared to the standard of care drugs alone and to 400mg celgosivir plus the standard of care for up to 12 weeks of therapy.

AnnKatrin Petersen, M.D., VP Clinical Development for MIGENIX commented, "The favorable tolerability experienced to date with 400mg per day of celgosivir in triple combination with pegylated interferon plus ribavirin, along with the clinically significant benefit demonstrated in our previous non-responder study, gives us confidence that increasing the dose to 600mg per day in combination therapy is an important development step for the optimization and advancement of celgosivir."

The currently enrolling Phase II viral kinetics study is a 12-week randomized, active-controlled study initially planned to enroll up to 20 patients in two treatment arms: (i) celgosivir (400mg once daily) plus peginterferon alfa-2b plus ribavirin ("PRC"); and (ii) peginterferon alfa-2b plus ribavirin ("PR"). Tolerability, pharmacokinetics and viral kinetics are being evaluated in the trial. The approved protocol amendment allows for the addition of a 600mg once daily dosing arm and the flexibility to increase the total number of patients in the study up to 50. With 15 patients enrolled to date, it is planned that approximately six additional patients will be enrolled, all in th
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
2. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
3. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
5. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
6. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
7. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
8. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
9. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
10. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
11. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., , ST. LOUIS, Nov. 24 /PRNewswire-First...) will be presenting at the NASDAQ OMX conference ... 7:45 AM US/CST. Interested parties may listen via...at http://inve s tor.sig m a a ldrich.com/...this file. ,, About Sigma-Aldrich: Sigma-...
(Date:11/24/2009)..., , SHANGHAI, Nov. 24 /PRNewswire-...ate Food & Drug Administration (SFDA) has appr...) for its oral insulin project,(Nodlin), an innova...ND,approval allows Biolaxy to initiate its first p...sorder characteristic of high blood glucose and po...
(Date:11/24/2009)..., , DUBLIN, November 24 /PRNewswire-Fi... the global specialty biopharmaceutical company, t...European Medicines Agency for,velaglucerase alfa, ...pment,for the treatment of Type 1 Gaucher disease....lucerase alfa that has been submitted, with previo...
(Date:11/24/2009)... Chemical Abstracts Servic..., reports that China,s patent office is now the wo...tions in chemistry. China trailed Japan,s patent o...n (WIPO), and the United States Patent and Tradema...ed the USPTO in 2005, WIPO in 2006, and exceeded J...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3
... To date, 60 specialty & fine,chemical and custom ...duled,to exhibit at the Pharma ChemOutsourcing Con...y., The conference and exhibition has already att...t September. The supplier community is attracted t...gh ratio of attendees from,pharmaceutical and biop...
...n by Dr. John St. John -, - Three Poster Present... ADDISON, Texas, May 28 ULURU Inc. (Amex: ULU ),...materials Congress, to be,held in Amsterdam from M...s,Vice President of Material Science, will give an...tion of three posters., The title of the invited ...
...ve Three Oncology Products in Clinic -, - Lead Ca...n-Small Cell Lung Canc...y 28th, at 11:00 a.m. Pacific ...y 28 /PRNewswire-FirstCall/ - Sonus,Pharmaceutical...s Inc., a,privately held biopharmaceutical develop...
Other Biology Technology:60 Specialty Chemical, Fine Chemical & Custom Synthesis Providers Will Exhibit at Pharma ChemOutsourcing on September 8-9 in New Jersey 2ULURU Inc. to Present at the 8th World Biomaterials Congress 2ULURU Inc. to Present at the 8th World Biomaterials Congress 3Sonus Pharmaceuticals and OncoGenex Technologies to Merge 2Sonus Pharmaceuticals and OncoGenex Technologies to Merge 3Sonus Pharmaceuticals and OncoGenex Technologies to Merge 4Sonus Pharmaceuticals and OncoGenex Technologies to Merge 5Sonus Pharmaceuticals and OncoGenex Technologies to Merge 6Sonus Pharmaceuticals and OncoGenex Technologies to Merge 7Sonus Pharmaceuticals and OncoGenex Technologies to Merge 8
(Date:11/23/2009)...s that a common oral bacterium may exacerbate auto...al, "Unique Lipids from a Common Human Bacterium R...hancing Autoimmunity," appears in the December 200... Multiple sclerosis (MS), a disease where the imm...cts nearly 1 in 700 people in the United States. ...
(Date:11/23/2009)...ailable for the H1N1 virus has been sent to vaccin...ination marks the first time vaccine has been sent..., Iowa State University,s Hank Harris, professor ...er and has been shipping preventive doses to swine...l weeks., The latest vaccines were shipped to a ...
(Date:11/23/2009)...E and USDA study concluded that 50 million U.S. ac...re could be converted from current uses to the pro... from which biomass could be harvested for use as ...n of a perennial grass monoculture from which subs... is expected to require nitrogen fertilizer. , A...
Breaking Biology News(10 mins):Factors from common human bacteria may trigger multiple sclerosis 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Switchgrass produces biomass efficiently 2Child Care Centers Throughout Mexico Being Crucified Unjustly Says Interchildren Inc 52045 1Child Care Centers Throughout Mexico Being Crucified Unjustly Says Interchildren Inc 52045 2Senators Baucus and Grassley Statement Regarding Physician Hospitals Despicable 52040 1Covanta Mendota Recognized for Its Exemplary Health and Safety Practices 52036 1Covanta Mendota Recognized for Its Exemplary Health and Safety Practices 52036 2Covanta Mendota Recognized for Its Exemplary Health and Safety Practices 52036 3
...CMay 28, 2008The 2008 American Society for Microbi...nvestigator Award is being presented to Adrian M. ...nfectious Diseases, NIAID, National Institutes of ...plied research in clinical microbiology or antimic...work studying infection susceptibility and resista...
...Man international scientific and professional orga...promoting the practical applications, technology a...nehas awarded $300,000 in research grants to suppo...ed by SNM,s Education and Research Foundation, rep...ular imaging and therapy by supporting the next ge...
..., R.I. July 14, 2008 The outlook for air quality... there,s little that the Chinese government can do... University of Rhode Island atmospheric chemist wh...the last five years by Chinese scientists. , "Th...nent to the pollutants that cause unhealthy air in...
Other Biology News:SNM awards $300,000 to support molecular imaging research 2URI researcher: China can't fully fix air quality problem for Olympics 2
Silencer Pre-designed siRNA, PAGE purified, annealed from Ambion
Custom siRNA, standard purity, annealed from Ambion
...ed to rapidly and reliably amplify unknown genomic...rovides hassle-free, ready-to use components, at a... ingredients are provided in each kit. The Genome ... cloning of genomic DNA, isolating promoter and re...
Bis-acrylamide, Ultra Pure from Research Organics, Inc.
Biology Products: